Boston Scientific Corp releases quarterly results, says elective surgery recover in July

"We've seen a very nice, consistent recovery with the sequential improvement," CEO Michael Mahoney said in a post earnings call.

The company said it was seeing a healthy mix of both rescheduled and new patient procedures.

It appears that the hospital systems are doing a much better job of a parallel path in managing COVID-19 patients and doing important elective procedures that patients need, Boston Scientific added.

A broad-based recovery, highlighted by all segments, was impressive, said Evercore ISI analyst Vijay Kumar.

Still, rising new cases of COVID-19 in some states in the United States fueled the possibility of new restrictions.

Excluding items, the company earned 8 cents per share, compared with analysts' estimates for a loss of 2 cents per share, according to IBES data from Refinitiv.

Revenue fell 23.8% to $2 billion, but was ahead of estimates of $1.73 billion.

Given the deferrable nature of Boston's portfolio, this quarter's results should be viewed as "better than feared," said Raymond James analyst Jayson Bedford.